Cited by 2,087Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Open access

Miller, Brian C., Sen, Debattama R., Al Abosy, Rose, Bi, Kevin, Virkud, Yamini V., LaFleur, Martin W., Yates, Kathleen B., Lako, Ana, Felt, Kristen, Naik, Girish S., Manos, Michael, Gjini, Evisa, Kuchroo, Juhi R., Ishizuka, Jeffrey J., Collier, Jenna L., Griffin, Gabriel K., Maleri, Seth, Comstock, Dawn E., Weiss, Sarah A., Brown, Flavian D., Panda, Arpit, Zimmer, Margaret D., Manguso, Robert T., Hodi, F. Stephen, Rodig, Scott J., Sharpe, Arlene H., Haining, W. Nicholas·2019·Nature Immunology

DOI 10.1038/s41590-019-0312-6PMC PMC6673650

Open this paper in CoChat — free account

Abstract

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8+ tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8+ TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8+ TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8+ TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8+ T cells might be an important component of improving the response to checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41590-019-0312-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citation
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citation
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072

Show all 53 references

Sorted by citations

Items 401–500 of 1,002

Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
Vadakekolathu, J. N., & Rutella, S. (2023) · Blood · doi:10.1182/blood.2023019961 · Cited by 77
Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells
Humblin, É., Korpas, I., Lu, J., Filipescu, D., van der Heide, V., Goldstein, S., Vaidya, A. B., Schanoski, A. S., Casati, B., Selvan, M. E., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg0878 · Cited by 72
CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 84
Cell and tissue engineering in lymph nodes for cancer immunotherapy
Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 73
Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy
Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 76
Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing
Li, X., Shen, Y., Zhang, L., Guo, X., & Wu, J. H. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188720 · Cited by 73
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity
Lee, C. Y. C., Kennedy, B. C., Richoz, N., Dean, I., Tuong, Z. K., Gaspal, F., Li, Z., Willis, C., Hasegawa, T., Whiteside, S. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44787-1 · Cited by 82
SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
López-Cobo, S., Fuentealba, J. R., Gueguen, P., Bonté, P.-E., Tsalkitzi, K., Chacón, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1350 · Cited by 72
Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects
Diggins, K. E., Serti, E., MUIR, V. S., Rosasco, M. G., Lü, T., Balmas, E., Nepom, G. T., Long, S. A., & Linsley, P. S. (2020) · JCI Insight · doi:10.1172/jci.insight.142680 · Cited by 71
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Liu, Y., Wang, C., Li, X., Dong, L., Yang, Q., Chen, M., Shi, F., Brock, M. V., Liu, M., Mei, Q., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002347 · Cited by 72
Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer
Wang, J., Li, R., Cao, Y., Gu, Y., Fang, H., Fei, Y., Lv, K., He, X., Lin, C., Liu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23356-w · Cited by 71
Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement
Chin, A. L., Jiang, S., Jang, E., Niu, L., Li, L., Jia, X., & Tong, R. (2021) · Nature Communications · doi:10.1038/s41467-021-25391-z · Cited by 71
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 72
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
Wang, Y., Wang, C., Qiu, J., Qu, X., Peng, J., Lu, C., Zhang, M., Zhang, M., Qi, X., Li, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003667 · Cited by 72
Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 76
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC
O’Melia, M. J., Manspeaker, M. P., & Thomas, S. N. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02792-5 · Cited by 69
Metabolic regulation of the cancer-immunity cycle
Patterson, L. F. S., & Vardhana, S. A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.002 · Cited by 73
Metabolic plasticity and regulation of T cell exhaustion
Li, F., Liu, H., Zhang, D., Ma, Y., & Zhu, B. (2022) · Immunology · doi:10.1111/imm.13575 · Cited by 73
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
Yan, Z., Wang, C., Wu, J., Wang, J., & Ma, T. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00267-6 · Cited by 84
Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq
Carmona, S. J., Siddiqui, I., Bilous, M., Held, W., & Gfeller, D. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1737369 · Cited by 69
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 77
Tim-3 mediates T cell trogocytosis to limit antitumor immunity
Pagliano, O., Morrison, R. M., Chauvin, J.-M., Banerjee, H., Davar, D., Ding, Q., Tanegashima, T., Gao, W., Chakka, S., Deblasio, R. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152864 · Cited by 73
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer
Thibaudin, M., Limagne, E., Hampe, L., Ballot, E., Truntzer, C., & Ghiringhelli, F. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03182-9 · Cited by 70
Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Wang, R., Singaraju, A., Marks, K. E., Shakib, L., Dunlap, G. S., Adejoorin, I., Greisen, S. R., Chen, L., Tirpack, A., Aude, C. A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1591 · Cited by 77
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
“…several sub- populations including ‘terminally exhausted’ and ‘progenitor exhausted’ populations, the former having higher cytolytic function and the latter being more important for responsiveness to anti-PD-1 therapy (Beltra et al., 2020; Hudson et al., 2019; Im et al., 2016; Miller et al., 2019).”
BackgroundSelf-citation
Exhausted T cells and epigenetic status
Zeng, Z., Wei, F., & Ren, X. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0338 · Cited by 73
Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade
Roussel, M., Le, K.-S., Granier, C., Gutierrez, F. L., Foucher, E. D., Gallou, S. L., Pangault, C., Xerri, L., Launay, V., Lamy, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003080 · Cited by 72
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
Niborski, L. L., Gueguen, P., Ye, M., Thiolat, A., Ramos, R. N., Caudana, P., Denizeau, J., Colombeau, L., Rodriguez, R., Goudot, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31504-z · Cited by 70
Immune checkpoint receptors in autoimmunity
Burke, K. P., Patterson, D. G., Liang, D., & Sharpe, A. H. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102283 · Cited by 70
Self-citation
Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 68
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics
Akinsipe, T., Mohamedelhassan, R., Akinpelu, A., Pondugula, S. R., Mistriotis, P., Avila, L. A., & Suryawanshi, A. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1302587 · Cited by 80
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 68
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Hoefsmit, E. P., Rozeman, E. A., Van, T. M., Dimitriadis, P., Krijgsman, O., Conway, J. W., da Silva, I. P., van der Wal, J. E., Ketelaars, S. L. C., Bresser, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001501 · Cited by 69
PDL1‐positive exosomes suppress antitumor immunity by inducing tumor‐specific CD8+ T cell exhaustion during metastasis
Chen, J., Song, Y., Miao, F., Chen, G., Zhu, Y., Wu, N., Pang, L., Chen, Z., & Chen, X. (2021) · Cancer Science · doi:10.1111/cas.15033 · Cited by 70
Application of Machine Learning for Cytometry Data
Hu, Z., Bhattacharya, S., & Butte, A. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.787574 · Cited by 72
Immune checkpoint blockade in HIV
Gubser, C., Chiu, C. Y. H., Lewin, S. R., & Rasmussen, T. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103840 · Cited by 69
Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection
D’Alise, A. M., Brasu, N., Intinis, C. D., Leoni, G., Russo, V., Langone, F., Baev, D. V., Micarelli, E., Petiti, L., Picelli, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7604 · Cited by 69
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
Cortés‐Selva, D., Perova, T., Skerget, S., Vishwamitra, D., Stein, S. J., Boominathan, R., Lau, O., Calara-Nielsen, K., Davis, C., Patel, J., et al. (2024) · Blood · doi:10.1182/blood.2023022823 · Cited by 73
Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages
Jing, W., Guo, X., Wang, G., Bi, Y., Han, L., Zhu, Q., Qiu, C., Tanaka, M., & Zhao, Y. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106012 · Cited by 73
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
Plesca, I., Tunger, A., Müller, L., Wehner, R., Lai, X., Grimm, M., Rutella, S., Bachmann, M. P., & Schmitz, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00364 · Cited by 71
Advances in Treatment of Progressive Multifocal Leukoencephalopathy
Bernard‐Valnet, R., Koralnik, I. J., & Pasquier, R. D. (2021) · Annals of Neurology · doi:10.1002/ana.26198 · Cited by 73
Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses
Yuen, V. W., Chiu, D. K., Law, C., Cheu, J. W., Chan, C. Y., Wong, B. P., Goh, C.-C., Zhang, M. S., Xue, H. D. G., Tse, A. P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.037 · Cited by 67
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
Lau, S. P., van Montfoort, N., Kinderman, P., Lukkes, M. M., Klaase, L., van Nimwegen, M., van Gulijk, M., Dumas, J., Mustafa, D. A. M., Lievense, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000772 · Cited by 70
FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells
Zhu, Z., Lou, G., Teng, X.-L., Wang, H., Luo, Y., Shi, W., Yihunie, K. D., Hao, S., DeGolier, K., Liao, C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01685-w · Cited by 69
Distinct epigenomic landscapes underlie tissue-specific memory T cell differentiation
Buquicchio, F. A., Fonseca, R., Yan, P., Wang, F., Evrard, M., Obers, A., Gutierrez, J. C., Raposo, C. J., Belk, J. A., Dániel, B., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.014 · Cited by 65
Lactylation‐Driven NUPR1 Promotes Immunosuppression of Tumor‐Infiltrating Macrophages in Hepatocellular Carcinoma
Cai, J., Zhang, P., Cai, Y., Zhu, G., Chen, S., Song, L., Du, J.-X., Wang, B., Dai, W., Zhou, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202413095 · Cited by 75
Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications
Tough, D. F., Rioja, I., Modis, L. K., & Prinjha, R. K. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.11.008 · Cited by 67
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 65
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 64
ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome
Parry, E. M., Lemvigh, C. K., Deng, S., Dangle, N. J., Ruthen, N. G., Knisbacher, B. A., Broséus, J., Hergalant, S., Guièze, R., Li, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.013 · Cited by 69
The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer
Topchyan, P., Lin, S., & Cui, W. (2023) · Immune Network · doi:10.4110/in.2023.23.e41 · Cited by 73
Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors
Ahn, T., Bae, E., & Seo, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.004 · Cited by 71
A comprehensive profile of TCF1+ progenitor and TCF1− terminally exhausted PD-1+CD8+ T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy
Wang, D.-K., Fang, J., Wen, S., Li, Q., Wang, J., Yang, L., Dai, W., Lu, H., Guo, J., Shan, Z., et al. (2022) · International Journal of Oral Science · doi:10.1038/s41368-022-00160-w · Cited by 67
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
Chan, S., Belmar, N. A., Ho, S., Rogers, B. M., Stickler, M. M., Graham, M., Lee, E., Tran, N., Zhang, D., Gupta, P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00334-9 · Cited by 67
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Apollonio, B., Spada, F., Petrov, N., Cozzetto, D., Papazoglou, D., Jarvis, P., Kannambath, S., Terranova-Barberio, M., Amini, R., Enblad, G., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166070 · Cited by 64
Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy
Verdeil, G., Lawrence, T., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2019) · Cancers · doi:10.3390/cancers11121832 · Cited by 64
Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice
Hu, H., Zakharov, P. N., Peterson, O. J., & Unanue, E. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019743117 · Cited by 63
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 63
Lighting up the tumor fire with low-dose irradiation
Herrera, F. G., Romero, P. J., & Coukos, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.006 · Cited by 68
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 78
Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance
Chen, C., Zhao, F., Peng, J., Zhao, D., Xu, L., Li, H., Ma, S., Peng, X., Sheng, X., Sun, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101686 · Cited by 66
P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors
Romagnani, A., Rottoli, E., Mazza, E. M. C., Rezzonico-Jost, T., Conti, B. D. P., Proietti, M., Perotti, M., Civanelli, E., Perruzza, L., Catapano, A. L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3807 · Cited by 63
Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes
Lledó-Delgado, A., Preston-Hurlburt, P., Currie, S., Clark, P., Linsley, P. S., Long, S. A., Liu, C., Koroleva, G., Martins, A. J., Tsang, J. S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177492 · Cited by 58
Proteotoxic stress response drives T cell exhaustion and immune evasion
Wang, Y., Ma, A., Song, N.-J., Shannon, A. E., Amankwah, Y. S., Chen, X., Wu, W., Wang, Z., Saadey, A. A., Yousif, A., et al. (2025) · Nature · doi:10.1038/s41586-025-09539-1 · Cited by 68
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 66
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
Li, S., Simoni, Y., Zhuang, S., Gabel, A. M., Ma, S., Chee, J., Islas, L., Cessna, A., Creaney, J., Bradley, R. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025570118 · Cited by 61
Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma
Wu, L., Li, L., Li, S., Liu, L., Xin, W., Li, C., Yin, X., Xu, X., Bao, F., & Hua, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.006 · Cited by 64
IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation
Lee, J., Lee, K., Bae, H., Lee, K., Lee, S., Ma, J., Jo, K., Kim, I., Jee, B., Kang, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117092 · Cited by 62
AKT kinases as therapeutic targets
Hassan, D., Menges, C. W., Testa, J. R., & Bellacosa, A. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03207-4 · Cited by 70
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 67
Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors
Brog, R. A., Ferry, S. L., Schiebout, C. T., Messier, C. M., Cook, W. J., Abdullah, L., Zou, J., Kumar, P., Sentman, C. L., Frost, H. R., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0536 · Cited by 62
CD39 + tissue-resident memory CD8 + T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer
Lee, Y. J., Kim, J. Y., Jeon, S. H., Nam, H., Jung, J. H., Jeon, M., Kim, E.-S., Bae, S. J., Ahn, J., Yoo, T.-K., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8390 · Cited by 56
Biomarkers of tumor-reactive CD4 + and CD8 + TILs associate with improved prognosis in endometrial cancer.
Palomero, J., Panisello, C., Lozano-Rabella, M., Tirtakasuma, R., Díaz-Gómez, J., Grases, D., Pasamar, H., Arregui, L., Duch, E. D., Guerra, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005443 · Cited by 65
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
Kim, H., Park, S., Han, K.-Y., Lee, N., Kim, H. M., Jung, H. A., Sun, J., Ahn, J. S., Ahn, M., Lee, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005509 · Cited by 65
Exhausted CD8+ T cells face a developmental fork in the road
Zander, R., & Cui, W. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.02.006 · Cited by 65
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
Ma, S., Ong, L.-T., Jiang, Z., Lee, W. C., Lee, P. L., Yusuf, M., Ditzel, H. J., Wang, Y., Chen, Q., Wang, W., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.12.001 · Cited by 62
Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma
Wu, X., Fan, Y., Chung, K. P. S., Leung, C. O. N., Leung, R. W. H., So, K. K. H., Lei, M. M. L., Chau, W. K., Tong, M., Yu, J. Q., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101900 · Cited by 66
CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape
Chen, Y., Xu, J., Wu, X., Yao, H., Yan, Z., Guo, T., Wang, W., Wang, P., Li, Y., Yang, X.-M., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00570-y · Cited by 60
Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation
Zhang, Y., Yeganeh, P. N., Zhang, H., Wang, S. Y., Li, Z., Gu, B., Lee, D.-J., Zhang, Z., Ploumakis, A., Shi, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01932-8 · Cited by 64
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
Li, Y.-R., Fang, Y., Niu, S., Zhu, Y., Chen, Y., Lyu, Z., Zhu, E., Tian, Y., Huang, J., Rezek, V. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56270-6 · Cited by 62
Exhausted CD8+ T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection
Sandu, I., Cerletti, D., Claassen, M., & Oxenius, A. (2020) · Nature Communications · doi:10.1038/s41467-020-18256-4 · Cited by 60
Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
Rowe, J. H., Elia, I., Shahid, O., Gaudiano, E. F., Sifnugel, N. E., Johnson, S., Reynolds, A. G., Fung, M. E., Joshi, S., LaFleur, M. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1301 · Cited by 59
Self-citation
Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance
Wagle, M. V., Vervoort, S. J., Kelly, M. J., Byl, W. V. D., Peters, T. J., Martin, B. P., Martelotto, L. G., Nüssing, S., Ramsbottom, K. M., Torpy, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23044-9 · Cited by 62
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes
Jaiswal, A., Verma, A., Dannenfelser, R., Melssen, M. M., Tirosh, I., Izar, B., Kim, T., Nirschl, C. J., Devi, K. S. P., Olson, W. C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.005 · Cited by 61
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function
Yü, P., Shan, J., Liu, Y., Liu, F., Wang, L., Liu, Z., Li, J., Yue, D., Wang, L., Chen, X., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03308-z · Cited by 67
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Chi, X., Luo, S., Ye, P., Hwang, W., Cha, J., Yan, X., & Yang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104771 · Cited by 62
Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
Morgan, D. M., Horton, B. L., Bhandarkar, V., Van, R., Dinter, T., Zagorulya, M., Love, J. C., & Spranger, S. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi3487 · Cited by 62
Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4
Pauneto, C. D. M. A., Riesenberg, B., Gandy, E. J., Kennedy, A. S., Clutton, G., Hem, J. W., Hurst, K. E., Hunt, E. G., Green, J. M., Miller, B. C., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.003 · Cited by 69
Self-citation
Postinfectious Epigenetic Immune Modifications — A Double-Edged Sword
DiNardo, A. R., Netea, M. G., & Musher, D. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028358 · Cited by 58
Intratumoral CD8 + T cells with stem cell–like properties: Implications for cancer immunotherapy
Held, W., Siddiqui, I., Schaeuble, K., & Speiser, D. E. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6863 · Cited by 58
COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases
Tovo, P.-A., Garazzino, S., Daprà, V., Pruccoli, G., Calvi, C., Mignone, F., Alliaudi, C., Denina, M., Scolfaro, C., Zoppo, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147481 · Cited by 59
Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy
Bachireddy, P., Azizi, E., Burdziak, C., Nguyen, V. N., Ennis, C. S., Maurer, K., Park, C. Y., Choo, Z.-N., Li, S., Gohil, S. H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109992 · Cited by 55
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade
Chen, I. X., Newcomer, K., Pauken, K. E., Juneja, V. R., Naxerova, K., Wu, M. W., Pinter, M., Sen, D. R., Singer, M., Sharpe, A. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002806117 · Cited by 55
Self-citation
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Sushil Kumar, K., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 56
Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Luo, R., Onyshchenko, K., Wang, L., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1591 · Cited by 61
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Hirayama, A. V. V., Kimble, E. L., Wright, J. H., Fiorenza, S., Gauthier, J., Voutsinas, J. M., Wu, Q. V., Yeung, C. C. S., Gazeau, N., Pender, B. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011287 · Cited by 60
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma
Chiffelle, J., Barras, D., Pétremand, R., Orcurto, A., Bobisse, S., Arnaud, M., Auger, A., Rodrigo, B. N., Ghisoni, E., Sauvage, C., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.014 · Cited by 68
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, D. H., Drake, C. G., & Rini, B. I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3323 · Cited by 57

Authors: Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., Manos, M., Gjini, E., Kuchroo, J. R., Ishizuka, J. J., Collier, J. L., Griffin, G. K., Maleri, S., Comstock, D. E., Weiss, S. A., Brown, F. D., Panda, A., Zimmer, M. D., Manguso, R. T., Hodi, F. S., Rodig, S. J., Sharpe, A. H., & Haining, W. N.
Affiliations: Broad Institute (US)
Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
Corresponding author: Haining, W. Nicholas
ORCID: Miller, Brian C.
Sen, Debattama R.
Al Abosy, Rose
Bi, Kevin
Virkud, Yamini V.
LaFleur, Martin W.
Yates, Kathleen B.
Lako, Ana
Felt, Kristen
Naik, Girish S.
Manos, Michael
Gjini, Evisa
Kuchroo, Juhi R.
Ishizuka, Jeffrey J.
Collier, Jenna L.
Griffin, Gabriel K.
Comstock, Dawn E.
Weiss, Sarah A.
Zimmer, Margaret D.
Manguso, Robert T.
Hodi, F. Stephen
Rodig, Scott J.
Sharpe, Arlene H.
Haining, W. Nicholas
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-18
Volume: 20
Issue: 3
Pages: 326-336
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/s41590-019-0312-6
PMC: PMC6673650
OpenAlex: W2913558101
Cited by: 2,087
References: 53
Citations by year: 2026: 319 · 2025: 334 · 2024: 358 · 2023: 300 · 2022: 276 · 2021: 269 · 2020: 176 · 2019: 55
FWCI: 81.19
Type: journal article
Language: en
Update notices: correction (2019-10-03)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (KL2TR002542)
National Heart, Lung, and Blood Institute (T32HL007627)
National Cancer Institute (T32CA207021, T32CA009172)
National Institute of General Medical Sciences (T32GM007753)
National Institute of Allergy and Infectious Diseases (R01AI115712, K23AI130408, U19AI133524, P01AI056299)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell exhaustion, CD8+ T cells, PD-1, anti-PD-1 therapy, immune checkpoint blockade, tumor-infiltrating lymphocytes, melanoma, T cell polyfunctionality, chronic viral infection, tumor control
MeSH terms: Animals, Female, Humans, Lymphocytic Choriomeningitis, Lymphocytic choriomeningitis virus, Melanoma, Experimental, Mice, Inbred C57BL, Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Antibodies, Blocking, Mice, Congenic, Cell Line, Tumor, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks